Design [acty]
Methods [inpr]
Of [spco]
Raloxifene [orch, phsu]
Heart study [diap]
Selective Estrogen Receptor Modulator [horm, phsu]
Low density lipoprotein [aapp, bacs, lipd]
Cholesterol [bacs, strd]
Vertebral Fracture [inpo]
Reduced [qlco]
Invasive Breast Cancer [neop]
postmenopausal [tmco]
Women [popg]
Osteoporosis [dsyn]
Raloxifene [orch, phsu]
Heart [bpoc]
Raloxifene [orch, phsu]
Heart [bpoc]
Trial [resa]
Design [acty]
Raloxifene 60 MG [clnd]
Compared [acty]
placebo [topp]
coronary [bpoc]
Events [evnt]
coronary [bpoc]
Myocardial Infarction [dsyn]
hospitalized [fndg]
Syndromes, Acute Coronary [dsyn]
Myocardial Infarction [dsyn]
Invasive Breast Cancer [neop]
Women [popg]
At risk [qlco]
coronary [bpoc]
Event [evnt]
Raloxifene [orch, phsu]
Heart [bpoc]
DOUBLE BLIND [resa]
placebo-controlled [resa]
Randomized Clinical Trial [inpr, resa]
postmenopausal [tmco]
Women [popg]
Aged [orga]
Equal [qlco]
Countries [geoa]
Women [popg]
eligible [idcn]
Randomization [resa]
postmenopausal [tmco]
Documented [hlca]
coronary heart disease [dsyn]
peripheral arterial disease [dsyn]
Multiple [qnco]
risk factors [qnco]
coronary heart disease [dsyn]
Estrogen [horm, phsu, strd]
Previous [tmco]
months [tmco]
EXCLUSION [ftcn]
Study [mnob]
terminated [idcn]
Minimum [qlco]
participants [popg]
experience [menp]
Primary Endpoint [irda]
coronary [bpoc]
secondary [neop]
End Point [qlco]
CARDIOVASCULAR [bdsy]
Myocardial Revascularization [topp]
Arterial [bpoc]
Revascularisation [topp]
Stroke [dsyn]
Hospitalization [hlca]
Mortality [qnco]
breast cancers [neop]
Fractures [inpo]
Venous [bpoc]
Thromboembolic events [patf]
Components [mnob]
Composite [qlco]
Primary Endpoint [irda]
coronary [bpoc]
Raloxifene [orch, phsu]
Heart [bpoc]
Information [idcn]
Risk Ratio [qnco]
Benefit [qnco]
Raloxifene [orch, phsu]
PREVENT [phsu]
acute [tmco]
coronary [bpoc]
Events [evnt]
Invasive Breast Cancer [neop]
Information [idcn]
Natural History [ocdi]
coronary heart disease [dsyn]
Women [popg]
coronary [bpoc]
Events [evnt]
